Merck Acquires Leukemia Treatment in $6.7 Billion Deal Ahead of Keytruda Exclusivity End

Merck has announced a $6.7 billion deal to acquire a leukemia treatment, a strategic move as the company prepares for the upcoming expiration of exclusivity for its blockbuster cancer drug, Keytruda.